Globus Medical (GMED)
(Delayed Data from NYSE)
$74.88 USD
+1.34 (1.82%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $74.90 +0.02 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.88 USD
+1.34 (1.82%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $74.90 +0.02 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum D VGM
Zacks News
AngioDynamics (ANGO) Q4 Earnings Match Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 0% and 5.27%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Globus Medical (GMED) Up 1.7% Since Last Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain Globus Medical (GMED) Now
by Zacks Equity Research
Globus Medical's (GMED) strong international growth and meaningful product launches raise investors' optimism.
Globus Medical (GMED) Completes First Cases With Excelsius3D
by Zacks Equity Research
Globus Medical's (GMED) Excelsius3D, when combined with ExcelsiusGPS, facilitates greater implant placement accuracy, lowers radiation exposure and reduces operative times.
Globus Medical (GMED) Q1 Earnings Miss Estimates, Margins Dip
by Zacks Equity Research
According to Globus Medical (GMED), its Q1 results reflect modest revenue growth against a difficult prior-year comparison, coupled with COVID-related revenue impacts in key countries.
Globus Medical (GMED) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of -8.70% and 1.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 20.83% and 5.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Globus Medical (GMED) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) Stock Fell on Preliminary Q1 Sales Results
by Zacks Equity Research
Globus Medical's (GMED) Q1 preliminary sales results reflect an increase in procedural volumes along with growth in Enabling Technologies business.
Orthopedics Device Space Gaining Prominence: 3 Stocks in Focus
by Riya Anand
Stocks like Orthofix Medical Inc. (OFIX), Stryker Corporation (SYK) and NuVasive, Inc. (NUVA) are likely to gain enormously from developments in the orthopedic space.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical's (GMED) better-than-expected results and strength in the U.S. Spine business.
Globus Medical (GMED) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.
Globus Medical (GMED) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 2.08% and 2.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 10% and 2.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Globus Medical (GMED) Q4 Earnings Expected to Decline
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of -7.27% and 1.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Encompass Health (EHC) to Spin Off Home Health & Hospice Unit
by Zacks Equity Research
Encompass Health (EHC) expects the Enhabit Home Health & Hospice spinoff to be completed in first-half 2022.
Ensign Group (ENSG) Up 7.4% in 3 Months: More Growth Ahead?
by Zacks Equity Research
Ensign Group (ENSG) is likely to keep growing on the back of Skilled services and impressive financial strength.
Molina Healthcare (MOH) Up 14.4% in 6 Months: Growth Ahead?
by Zacks Equity Research
Molina Healthcare (MOH) is likely to keep growing on the back of increasing membership and higher premium revenues.
Select Medical (SEM) '21 Sales View Up, Labor Costs Ail Profits
by Zacks Equity Research
Select Medical Holdings (SEM) estimates net operating revenues for 2021 to be $6.2 billion, up from the previous expectations.
Ford Motor and IRobot have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ford Motor and IRobot have been highlighted as Zacks Bull and Bear of the Day
Omicron Hits Elective MedTechs, 3 Subsectors Likely to Thrive
by Urmimala Biswas
Here we discuss three major subsectors of MedTech and three constituent stocks, OPCH, GMED and OMCL for which the change in the scenario has opened up enormous growth prospects.
Here's Why You Should Hold on to Globus Medical (GMED) for Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED), backed by strength in the Enabling Technologies arm and ExcelsiusGPS platforms.
Here's Why You Should Hold on to Globus Medical (GMED) for Now
by Zacks Equity Research
Investors are optimistic about Globus Medical's (GMED) better-than-expected earnings and robust ExcelsiusGPS performance.